Bionote USA attended the Western Veterinary Conference to be held March 6th to March 9th, 2022 at the Mandalay Bay Convention Center in Las Vegas, Nevada.

WVC’s Annual Conference is one of the largest, most influential gatherings of veterinary professionals in the world.

Bionote USA communicated with veterinary workers and vets who attended the conference through participation in the booth about how Vcheck could develop and help veterinary medicine.

On this day, renowned Dr. Rozanski sponsored by Bionote, spoke about the role of NT-proBNP in clinical decision making and the benefits of point-of-care testing.

NT-proBNP is correlated with heart size and systolic function, suggesting that the concentrations can be used to detect dogs with early disease.

In addition, Vcheck Canine NT-proBNP is an in vitro diagnostic test kit for the quantitative measurement of NT-proBNP concentration in canine serum. This test kit precisely quantifies the degree of elevation in NT-proBNP levels in dogs.

The ability to distinguish cardiac from non-cardiac causes of respiratory signs is important for further decisions on diagnostics and therapy. NT-proBNP allows distinguishing cardiac from respiratory disease in dogs with dyspnea.

Also, this marker helps to detect dogs with Myxomatous Mitral Valve Degeneration (MMVD), which is the most common heart disease in dogs. In dogs with stable Congestive Heart Failure (CHF) due to MMVD, NT-proBNP is of value in monitoring the effectiveness of medical treatment for CHF.

In large breeds, Dilated Cardiomyopathy (DCM) is the most common cause of heart disease. Annual screening tests are recommended to determine if DCM is present even if dogs at elevated risk are healthy. The measurement of NT-proBNP increases the diagnostic accuracy with Holter monitoring (91% accuracy).

Vcheck Canine NT-proBNP: The one-step test procedure is easy to follow and provides fast results within 15 minutes using serum samples from dogs.

Bionote USA completed the 2022 Western Veterinary Conference, and in addition, Bionote KOREA and Bionote CHINA also plan to hold various external activities and conferences.